Inventiva will present three abstracts at AASLD The Liver Meeting® 2026, held November 5-9, 2026, in Denver, Colorado, concerning lanifibranor in MASH. Phase 3 NATiV3 topline results are expected in the fourth quarter of this year.
IVA · Inventiva S.A.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Short volume, last session
- 43%
- Last earnings
- Sep 28, 2026
- Price history
- Jul 2020 to Nov 2026
Up next
Latest documents
Inventiva S.A. completed a June 2026 refinancing, drew €75.0 million, had €166.1 million in cash and cash equivalents at June 30, 2026, and completed NATiV3’s final patient visit, targeting topline results in the fourth quarter of 2026.
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
IVA
this stock
Inventiva S.A.
|
$750.78M | -32.5% | — | — | 4.3% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$130.58B | +13.6% | +46.2% | 33.2 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$95.24B | +19.3% | +20.8% | 20.4 | 2.1% |
|
MRNA
Moderna, Inc.
|
$78.90B | +561.2% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$62.17B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Oct 6, 2026
- This year
- 20
Inventiva will present three abstracts at AASLD The Liver Meeting® 2026, held November 5-9, 2026, in Denver, Colorado, concerning lanifibranor in MASH. Phase 3 NATiV3 topline results are expected in the fourth quarter of this year.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| IVA | -14.7% | -15.4% | -23.2% | -14.0% | -32.5% |
| SPY | -8.6% | -9.2% | -9.2% | -8.7% | +1.2% |
| vs SPY | -6.1% | -6.1% | -14.1% | -5.3% | -33.6% |